Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. - Wikidata - awgldk - TriplyDB

Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.

Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.

http://www.wikidata.org/entity/Q36849036

about

Acromegaly pathogenesis and treatment Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly A systematic literature review of cerebrospinal fluid biomarkers in delirium Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects.Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer.Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.The GH/IGF-1 Axis and Heart Failure.Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.Obesity alters gene expression for GH/IGF-I axis in mouse mammary fat pads: differential role of cortistatin and somatostatin.Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly Noncanonical suppression of GH-dependent isoforms of cytochrome P450 by the somatostatin analog octreotide.Changing paradigms in the surgical and medical management of acromegaly.Peptide receptor targeting in cancer: the somatostatin paradigm.Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode.Nanomedicines in the treatment of acromegaly: focus on pegvisomant.Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.Growth hormone-independent suppression of growth hormone-dependent female isoforms of cytochrome P450 by the somatostatin analog octreotide.Constitutive somatostatin receptor activity determines tonic pituitary cell response.Current therapy and drug pipeline for the treatment of patients with acromegaly.Somatostatin analog and pegvisomant combination therapy for acromegaly.Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.Octreotide long-acting repeatable for acromegaly.Lanreotide autogel in acromegaly - a decade on.Effect of feed restriction and subsequent re-alimentation on hormones and genes of the somatotropic axis in cattle.The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.New therapeutic agents for acromegaly.Current and future medical treatments for patients with acromegaly.The aging suppressor klotho: a potential regulator of growth hormone secretion.Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance.Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon?Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells.Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience.Somatostatin inhibits hepatic growth hormone receptor and insulin-like growth factor I mRNA expression by activating the ERK and PI3K signaling pathways.Central [CNS] and Peripheral [Gastric Tissue] Selective Monitoring of Somatostatin (SRIF) with Micro-Sensor and Voltammetry in Rats: Influence of Growth Factors (GH, EGF).Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients.

P2860

Q24647360-613F253F-06CA-4F64-95D0-A8AC159E03B9 Q26741026-38BC36BF-9514-45EB-A3D5-132929AF787C Q27001646-496D4026-ACC5-44B3-903C-57E519B72EA1 Q30434315-83AD8080-6049-4816-AE6C-ED095DB9A9C3 Q33424008-2BB7D3E5-8B0F-41A2-980F-2A2BB0E515C1 Q33579615-635CAE46-3F2D-442B-BBB9-9235C4799DAF Q33654009-F3D6268D-AE55-41F8-B243-F2A8AAFDEFDB Q33772673-0EF35BA2-2C86-4F49-8FB0-064BF84C1CF7 Q35217246-05C787EB-923A-4AB5-82CB-BEC9CBBF0652 Q35977997-261FADEA-2230-4DEF-AEB9-12FC6DC7E6A0 Q36236809-F0B8FD9C-E308-45ED-9607-09DD32709FBE Q36517205-8C1854E9-A66D-4114-865A-8898B4DF01AE Q36605363-EB7613E3-E52E-4D1D-A583-C79246CBE312 Q36638046-F024ABEA-94B9-404F-9E56-F00723171D5C Q36662452-FA91313A-C67C-4BF1-BCDE-B3C337821AB7 Q36920317-58DD56A3-1040-400B-B5AC-E4C67E6E2CA7 Q37029532-BC08FB46-8F89-4AD3-9CB8-428707A8B071 Q37138295-E11D6DFD-D397-425C-811E-66BBFD58D6D0 Q37302367-3C58093A-C217-4E48-955F-EFCFA54E45B7 Q37483633-819F2129-D448-4214-BDFB-992950E8E8EE Q37599321-9E948F99-77E9-4EBC-B8D1-B848B803C139 Q37663006-E42B3F03-D6B4-452F-86D4-EE5F8A26DB0A Q37898112-62DCD2A0-0543-4574-A9AE-2C56C267D1DE Q37990556-41A8B374-BC8C-4C68-8FC4-A00223EC5A82 Q38259409-0EB96EAE-FFB6-469C-8452-939E91DE535B Q38299412-4D1B8D08-0BE0-415C-A9BC-76BB5ADC5B84 Q38441413-EF5DFA8B-4996-4383-B135-AECE13760990 Q38648739-1DB0F975-2DF5-42FC-BC2A-A63C9D7CBEBC Q38847622-D0A95AA7-D458-45B9-BB48-7DF8E336B209 Q38983596-2411536D-F437-4364-AAD3-1C76D6F79E4B Q38990078-FCC93AEA-9F22-488C-82AA-F3E0E8858B26 Q41458291-FB0345E1-CAE1-487E-B714-80E720BADC5E Q42196860-0496CB4D-87FE-4626-91BE-FE7779530A70 Q42842968-0419206D-B005-4DDC-BF94-B3F8A93D91CE Q43078115-2C0780A1-F283-46D0-A280-DB5EA1DCDC9B Q45912383-379348AC-8AB8-4F72-9780-B3B57A9438A2 Q46582431-F6C80B1E-28D5-43F7-9A93-02A17A88901C Q47103563-5B35746D-DEF8-4E3B-9593-D253D0120C73 Q50884057-BDA55302-65E8-4682-9CAC-0A95BA0928CF Q51271616-36D964B0-79EF-40D1-B472-1AB42AA6F361

P2860

Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.

http://www.wikidata.org/entity/Q36849036

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.

@en

type

label

Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.

@en

prefLabel

Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.

@en

P1433

Q36849036-C46D4342-065E-4FCC-9E91-3D8E9875A487

P1476

Q36849036-97B3A580-F2E6-42A5-AC80-0B3CB4662BAE

P2093

Q36849036-064C82E2-F9B5-4948-83F5-D8B471543C39

Q36849036-10939BE8-BFCD-44D9-92FB-FE35D45CD152

Q36849036-36A33493-D0E8-4F7B-B692-FAEAE562B14E

Q36849036-64BFACED-4B97-4D49-ABF0-845C59FB0CE2

Q36849036-8656267D-6B5B-4DD8-8E66-244297B509EE

Q36849036-9F12A7BC-234F-4BF7-A3FC-BB23C9BC39A7

P2860

Q36849036-0BCF78E9-A4EA-44CB-A1A9-5A2B671E73E2

Q36849036-0DD4CCEC-205F-46D9-8DD9-801CBE08CE1E

Q36849036-1149607F-9443-4E52-A9F0-905BE35CD3D9

Q36849036-1771881B-8EC4-498A-97B8-5430F2D02661

Q36849036-33E3E81D-B449-4444-A679-B46A7588A78D

Q36849036-349C2F71-1886-484B-A27E-336625A8B6F4

Q36849036-34F48E69-A1D4-4DE1-87C8-5FE35C3B9DF7

Q36849036-37AC8D1F-4B57-4675-BABE-6881B9377980

Q36849036-435E971A-36EA-45D9-AE69-06273F0E28EC

Q36849036-45A43C67-A939-44E3-818E-13BCF539ABBB

P304

Q36849036-584FEB06-6948-40D7-801D-12EB1DB64FFA

P31

Q36849036-691C0D99-BB81-44E1-AFD5-F45C6A4E2BAC

P356

Q36849036-77EFB45B-B9E1-490D-AEC5-2300FD2BB247

P407

Q36849036-FDA62CA3-C0DE-4336-B979-70107283224E

P433

Q36849036-FA8B5D0D-5162-4CED-9113-E218E9E016AC

P478

Q36849036-CCA30D14-BD43-4601-B65C-66A52852D834

P577

Q36849036-753237F5-503A-4019-A660-DC8637EA2BE7

P5875

Q36849036-0C262E8C-8F0E-4EA2-86E5-D309932E4704

P698

Q36849036-1A046903-6B9D-484C-BFBC-31FFEF900BA7

P932

Q36849036-32A49453-A4DB-44D9-859C-CFD0CFD72EF3

P356

P1433

Journal of Clinical Investigation

P1476

Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.

@en

P2093

Kiwon Kim

http://www.w3.org/2001/XMLSchema#string

Marjorie Chelly

http://www.w3.org/2001/XMLSchema#string

Robert D Murray

http://www.w3.org/2001/XMLSchema#string

Shlomo Melmed

http://www.w3.org/2001/XMLSchema#string

Song-Guang Ren

http://www.w3.org/2001/XMLSchema#string

Yutaka Umehara

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of protein tyrosine phosphatases with specificity for the ligand-activated growth hormone receptor

Insulin inhibits growth hormone signaling via the growth hormone receptor/JAK2/STAT5B pathway

Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.

Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.

Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells.

Somatostatin receptors present knowledge and future directions.

The somatomedin hypothesis: 2001.

Guidelines for acromegaly management.

Differential expression of alternative 5' untranslated regions in mRNAs encoding rat insulin-like growth factor I.

Mechanism of signaling by growth hormone receptor.

P304

349-356

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI19933

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P577

2004-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8422894

http://www.w3.org/2001/XMLSchema#string

P698

15286801

http://www.w3.org/2001/XMLSchema#string

P932

484973

http://www.w3.org/2001/XMLSchema#string